Climb Bio, Inc. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 24/100
What the filing says
Climb Bio adopted a non-employee director compensation policy effective June 29, 2026. Cash compensation includes Board retainer of $40,000 annually plus committee retainers ($5,000–$7,500), with chair increments of $30,000 (Board) or $7,500 (committees). Equity compensation grants initial options for 80,000 shares (capped at $700,000 fair value) vesting monthly over 3 years, and annual options for 40,000 shares (capped at $350,000) vesting after 1 year, both with full acceleration upon Change in Control.
Why this rating
Routine director compensation policy adoption; cash retainers total ~$62.5K per director annually, immaterial relative to $44.8M company market cap; equity grants are standard governance practice.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.